IL188355A0 - Methods of treatment using hydroquinone ansamycins - Google Patents

Methods of treatment using hydroquinone ansamycins

Info

Publication number
IL188355A0
IL188355A0 IL188355A IL18835507A IL188355A0 IL 188355 A0 IL188355 A0 IL 188355A0 IL 188355 A IL188355 A IL 188355A IL 18835507 A IL18835507 A IL 18835507A IL 188355 A0 IL188355 A0 IL 188355A0
Authority
IL
Israel
Prior art keywords
benzoquinone
hydroquinone
treatment
methods
ansamycins
Prior art date
Application number
IL188355A
Other languages
English (en)
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of IL188355A0 publication Critical patent/IL188355A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL188355A 2005-07-13 2007-12-24 Methods of treatment using hydroquinone ansamycins IL188355A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/180,314 US20060019941A1 (en) 2003-12-23 2005-07-13 Analogs of benzoquinone-containing ansamycins and methods of use thereof
PCT/US2006/027113 WO2007009007A2 (en) 2005-07-13 2006-07-13 Methods of treatment using hydroquinone ansamycins

Publications (1)

Publication Number Publication Date
IL188355A0 true IL188355A0 (en) 2008-08-07

Family

ID=37637939

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188355A IL188355A0 (en) 2005-07-13 2007-12-24 Methods of treatment using hydroquinone ansamycins

Country Status (16)

Country Link
US (1) US20060019941A1 (enExample)
EP (1) EP1904057B1 (enExample)
JP (1) JP2009501234A (enExample)
KR (1) KR20080030093A (enExample)
CN (1) CN101267816A (enExample)
AT (1) ATE451919T1 (enExample)
AU (1) AU2006268196A1 (enExample)
BR (1) BRPI0612870A2 (enExample)
CA (1) CA2612506A1 (enExample)
DE (1) DE602006011161D1 (enExample)
ES (1) ES2337397T3 (enExample)
IL (1) IL188355A0 (enExample)
MX (1) MX2007016469A (enExample)
NO (1) NO20080304L (enExample)
WO (1) WO2007009007A2 (enExample)
ZA (1) ZA200800906B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1716119B1 (en) 2003-12-23 2013-03-06 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US7608611B2 (en) * 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
JP2008543941A (ja) * 2005-06-21 2008-12-04 インフィニティ・ディスカバリー・インコーポレイテッド アンサマイシン製剤およびその使用方法
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2134338A1 (en) * 2007-04-12 2009-12-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
WO2009026548A1 (en) 2007-08-23 2009-02-26 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
CA2733514C (en) 2008-08-21 2017-10-24 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
CA2739928A1 (en) * 2008-10-15 2010-04-22 Infinity Pharmaceuticals, Inc. Ansamycin hydroquinone compositions
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CA2943894A1 (en) 2014-05-01 2015-11-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
CN114259564B (zh) * 2021-11-30 2023-03-14 清华大学 Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用
CN115227692A (zh) * 2022-09-05 2022-10-25 中国医学科学院基础医学研究所 Reblastatin在制备治疗慢性惊厥的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) * 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
KR940703923A (ko) * 1992-01-06 1994-12-12 알렌 제이. 스피겔 4,5-디히드로겔다나마이신 및 그의 하이드로퀴논의 제조 방법 및 용도(Process and Uses for 4,5-Dihydrogeldanamycin and Its Hydroquinone)
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
WO1995001342A1 (en) * 1993-06-29 1995-01-12 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6890917B2 (en) * 2001-03-30 2005-05-10 The United States Of America As Represented By The Department Of Health And Human Services Geldanamycin derivative and method of treating cancer using same
WO2003013430A2 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
EP1472230B1 (en) * 2002-02-08 2009-06-17 Conforma Therapeutic Corporation Ansamycins having improved pharmacological and biological properties
EP1716119B1 (en) * 2003-12-23 2013-03-06 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US7608611B2 (en) * 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor

Also Published As

Publication number Publication date
BRPI0612870A2 (pt) 2010-11-30
US20060019941A1 (en) 2006-01-26
JP2009501234A (ja) 2009-01-15
CN101267816A (zh) 2008-09-17
ES2337397T3 (es) 2010-04-23
AU2006268196A1 (en) 2007-01-18
KR20080030093A (ko) 2008-04-03
NO20080304L (no) 2008-02-29
MX2007016469A (es) 2008-04-22
ZA200800906B (en) 2009-07-29
CA2612506A1 (en) 2007-01-18
DE602006011161D1 (de) 2010-01-28
ATE451919T1 (de) 2010-01-15
EP1904057A2 (en) 2008-04-02
WO2007009007A3 (en) 2007-05-03
WO2007009007A2 (en) 2007-01-18
EP1904057B1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
IL188355A0 (en) Methods of treatment using hydroquinone ansamycins
NO20062707L (no) Analoger av benzokinon-inneholdende ansamyciner for behandling av kreft
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
PT2368550E (pt) Modulador do receptor de androgénios para o tratamento de cancro da próstata e doenças associadas ao receptor de androgénios
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
TW200510301A (en) Novel compounds
TW200612892A (en) Novel compounds
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
EA201001286A1 (ru) Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза
BRPI0507968A (pt) oxidação de compostos orgánicos a ph alto
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
ECSP088628A (es) Moduladores de receptores cannabinoides
PH12012502212A1 (en) Nitrogen heterocyclic compounds usefulas pde10 inhibitors
MX2009008096A (es) Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
TW200728258A (en) Novel compounds
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
UA104861C2 (uk) Похідні хроману як модулятори trpv3
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
BR112015011986A2 (pt) síntese de compostos de absorção de uv
WO2008128782A3 (en) Photochemical process for the preparation of a previtamin d